A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

To be considered for this study, you would generally need to be an adult over 18 years old. Your overall health and ability to perform daily activities, as assessed by a doctor, would need to be in a certain range (known as an ECOG score of 0 to 2). If you are of childbearing potential, you would need to use contraception during and for a period after the study treatment. If you have previously received treatment that targets a protein called CD19, doctors would need to confirm your cancer cells still have CD19 on their surface.

Beyond these general guidelines, each group (substudy) within this research has its own specific requirements. For example, if you have CLL or SLL, your doctor would need to confirm that you require treatment based on specific criteria, or that your lymphoma has a measurable size. You might also need to have received a certain number of previous cancer treatments. For those with Mantle-cell Lymphoma, your diagnosis would need to be confirmed, and the cancer would need to be at a certain stage with measurable sites and you would have had previous treatments.

If you have Large B-cell Lymphoma, you would need to be no older than 79 years old, have a healthy heart function, and your lymphoma would need to be measurable. The study is particularly interested in those with newly diagnosed or advanced disease that has come back or not responded to earlier treatments. However, certain conditions would stop you from taking part, such as having lymphoma in your brain or spinal cord, or having had certain types of surgery very recently.

If you join this study, your involvement would be divided into three main parts. First, there's a 'screening period' which lasts up to 28 days. During this time, you'll have various tests and evaluations to check if you meet all the requirements for taking part.

Next is the 'treatment period,' where you would receive the study medication, surovatamig, either on its own or in combination with other anti-cancer drugs. The team would carefully monitor your health and how you respond to the treatment. The number of visits and specific assessments (like blood tests, scans, and physical exams) will depend on which treatment group you are in and will be explained in detail by the study team.

Finally, there's a 'follow-up period' after your treatment ends. This is to keep an eye on your health and check for any long-term effects of the treatment. The total duration of your participation can vary, but the study team will provide you with a clear timeline. You would also need to adhere to specific contraception requirements during and for several months after treatment.